About Veracyte
Veracyte is a company based in San Francisco (United States) founded in 2008.. Veracyte has raised $67.9 million across 6 funding rounds from investors including Kleiner Perkins, TPG and General Electric. The company has 824 employees as of December 31, 2024. Veracyte has completed 4 acquisitions, including Allegro Diagnostics, C2i Genomics and Decipher. Veracyte offers products and services including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, and Decipher Bladder Genomic Classifier. Veracyte operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter San Francisco, United States
- Employees 824 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Veracyte, Inc.
-
Annual Revenue
$445.76 M23.46as on Dec 31, 2024
-
Net Profit
$24.14 M0as on Dec 31, 2024
-
EBITDA
$56.67 M274.69as on Dec 31, 2024
-
Total Equity Funding
$67.9 M (USD)
in 6 rounds
-
Latest Funding Round
$45 M (USD), Debt – Conventional
Mar 28, 2016
-
Investors
Kleiner Perkins
& 9 more
-
Employee Count
824
as on Dec 31, 2024
-
Investments & Acquisitions
Allegro Diagnostics
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Veracyte
Veracyte is a publicly listed company on the NASDAQ with ticker symbol VCYT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Veracyte
Veracyte offers a comprehensive portfolio of products and services, including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, and Decipher Bladder Genomic Classifier. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Test for thyroid cancer diagnosis using genomic data.
Assists in prostate cancer prognosis and treatment decisions.
Evaluates breast cancer risk through genomic analysis.
Supports bladder cancer assessment with molecular insights.
Unlock access to complete
Unlock access to complete
Funding Insights of Veracyte
Veracyte has successfully raised a total of $67.9M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $45 million completed in March 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Debt – Conventional — $45.0M
-
First Round
First Round
(01 Jun 2008)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2016 | Amount | Debt – Conventional - Veracyte | Valuation |
investors |
|
| Apr, 2015 | Amount | Post-IPO - Veracyte | Valuation |
investors |
|
| Sep, 2014 | Amount | Post-IPO - Veracyte | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Veracyte
Veracyte has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Kleiner Perkins, TPG and General Electric. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment opportunities in healthcare are managed by Broadfin Capital.
|
Founded Year | Domain | Location | |
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Veracyte
Veracyte has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Allegro Diagnostics, C2i Genomics and Decipher. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Liquid biopsy for post-cancer surgery tumor monitoring is provided.
|
2019 | ||||
|
Developer of diagnostic product for colon cancer
|
2015 | ||||
|
Genomic test solutions for cancer diagnosis are developed.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Veracyte
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Veracyte Comparisons
Competitors of Veracyte
Veracyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| domain | founded_year | HQ Location |
Health risks are identified through online genetic and diagnostic testing.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Veracyte
Frequently Asked Questions about Veracyte
When was Veracyte founded?
Veracyte was founded in 2008.
Where is Veracyte located?
Veracyte is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Veracyte a funded company?
Veracyte is a funded company, having raised a total of $67.9M across 6 funding rounds to date. The company's 1st funding round was a Post-IPO of $12.8M, raised on Jun 01, 2008.
How many employees does Veracyte have?
As of Dec 31, 2024, the latest employee count at Veracyte is 824.
What is the annual revenue of Veracyte?
Annual revenue of Veracyte is $445.76M as on Dec 31, 2024.
What does Veracyte do?
Veracyte was founded in 2008 and is headquartered in San Francisco, United States. Genomics-based diagnostics for cancer are developed and offered by the company within the healthcare sector. Products such as the Percepta test are utilized to evaluate lung cancer risk through analysis of bronchial epithelial cells, while the Afirma Thyroid FNA Analysis identifies benign thyroid nodules. Additional tests, including the Envisia classifier for idiopathic pulmonary fibrosis, are under development.
Who are the top competitors of Veracyte?
Veracyte's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
What products or services does Veracyte offer?
Veracyte offers Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, and Decipher Bladder Genomic Classifier.
Is Veracyte publicly traded?
Yes, Veracyte is publicly traded on NASDAQ under the ticker symbol VCYT.
How many acquisitions has Veracyte made?
Veracyte has made 4 acquisitions, including Allegro Diagnostics, C2i Genomics, and Decipher.
Who are Veracyte's investors?
Veracyte has 10 investors. Key investors include Kleiner Perkins, TPG, General Electric, Camber Capital Management, and Broadfin Capital.
What is Veracyte's ticker symbol?
The ticker symbol of Veracyte is VCYT on NASDAQ.